(Jan. 2 issue), 1 the combination of nivolumab and ipilimumab resulted in an unprecedented increase in overall and melanoma-specific survival, as compared with ipilimumab alone. We should be wary ...

Two neoadjuvant immunotherapy combinations for head and neck cancer substantially increased the response rate versus a single ...

In a study of patients with advanced melanoma, the prevalence of cutaneous immune–related adverse events (cirAEs) associated with nivolumab/relatlimab combination therapy was 21.5%, with rash ...